Six peptides received narrow advisory support for potential 503A Bulks List inclusion, an atypical outcome given FDA staff recommendations against all seven under review. FDA reviewers cited short, underpowered studies insufficient for safety/efficacy across proposed indications, including
FDA Panel Backs 6 Peptides for Compounding | AJMCThe Pharmacy Compounding Advisory Committee narrowly recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon for the 503A Bulks List.www.ajmc.com